natgillin/translations-raw huggingface dataset:
A population kinetic analysis did not show any effect of age (range 18 to 65 years) or gender on cladribine pharmacokinetics. 
Populacijske analize kinetike niso pokazale nikakršnih znakov vpliva starosti (razpon od 18 do 65 let) ali spola na farmakokinetiko kladribina.
Latent infections may be activated, including tuberculosis or hepatitis. 
Aktivirajo se lahko latentne okužbe, vključno s tuberkulozo ali hepatitisom.
Your doctor will tell you the number of tablets to take 
Zdravnik bo določil število tablet, ki jih morate jemati
The prescriber / patient guide should include information about the following safety concerns: 
Vodnik za zdravnika, ki bo zdravilo predpisoval/bolnika, naj vključuje informacije o naslednjih pomislekih glede varnosti:
- if you are allergic to cladribine or any of the other ingredients of MAVENCLAD (listed in section 6). 
- če ste alergični na kladribin ali katero koli sestavino zdravila MAVENCLAD (navedeno v poglavju 6).
Raise the blister pack by pushing your finger through the hole in the tray. 
Dvignite pretisni omot, tako da prst potisnete skozi luknjo v nosilcu.
You may have to have the blood irradiated to prevent complications. 
Morda bo treba za preprečitev zapletov kri obsevati.
Safety and efficacy in patients with moderate or severe renal impairment have not been established. 
Varnost in učinkovitost pri bolnikih z zmerno ali hudo ledvično okvaro nista bili dokazani.
However, net effects in terms of potential cladribine exposure alterations are difficult to predict. 
Vendar je dejanske učinke v smislu možnih sprememb izpostavljenosti kladribinu težko napovedati.
In the clinical study data base of cladribine in MS (1,976 patients, 8,650 patient years) no case of PML has been reported. 
V podatkovni bazi klinične študije s kladribinom pri MS (1.976 bolnikov, 8.650 bolnikov-let) niso poročali o nobenem primeru PML.
Clinical studies with oral cladribine in MS did not include patients over 65 years of age; therefore, it is not known whether they respond differently from younger patients. 
V klinične študije s peroralnim kladribinom pri MS niso bili vključeni bolniki starejši od 65 let, zato ni znano, ali je njihov odziv drugačen kot pri mlajših bolnikih.
Dose and time dependence 
Odvisnost od odmerka in časa
The most important side effect is a reduction in the number of white blood cells called lymphocytes (lymphopenia), which is very common (may affect more than 1 in 10 people) and may be severe. 
Najpomembnejši neželeni učinek je zmanjšanje števila belih krvnih celic, imenovanih limfociti (limfopenija), ki je zelo pogost (pojavi se lahko pri več kot 1 od 10 bolnikov) in je lahko resen.
Patients with lymphocyte counts below 500 cells/mm³ should be actively monitored for signs and symptoms suggestive of infections, in particular herpes zoster. 
Bolnike s številom limfocitov pod 500 celic/mm³ je treba aktivno nadzirati glede znakov in simptomov, ki nakazujejo okužbe, še posebno s herpesom zosterjem.
It is recommended that the daily cladribine doses in each treatment week be taken at intervals of 24 hours at approximately the same time each day. 
Priporoča se, da se dnevni odmerki kladribina v vsakem tednu zdravljenja jemljejo v 24-urnih časovnih presledkih, vsak dan ob približno enakem času.
Patients who had completed the CLARITY study could be enrolled in CLARITY Extension. 
Bolniki, ki so zaključili študijo CLARITY, so se lahko vključili v podaljšano študijo (CLARITY Extension).
If you get pregnant more than 6 months after the last dose in year 1, no safety risk is expected but this will mean that you cannot receive treatment with MAVENCLAD while you are pregnant. 
Če zanosite več kot 6 mesecev po zadnjem odmerku v prvem letu, ni pričakovati nobenega tveganja glede varnosti, vendar to pomeni, da med nosečnostjo ne morete prejemati zdravljenja z zdravilom MAVENCLAD.
Cladribine can reduce the body's immune defence and may increase the likelihood of infections. 
Kladribin lahko zmanjša imunsko obrambo telesa in zviša možnost okužb.
If necessary, the treatment course in year 2 can be delayed for up to 6 months to allow for recovery of lymphocytes. 
Če je potrebno, se lahko cikel zdravljenja v 2. letu preloži za do 6 mesecev, da se omogoči izboljšanje števila limfocitov.
Short-term corticosteroids can be used when advised by your doctor. 
Kratkotrajna uporaba kortikosteroidov je možna, če tako svetuje vaš zdravnik.
If you require blood transfusions, tell the doctor that you are taking MAVENCLAD. 
Če potrebujete transfuzijo krvi, povejte zdravniku, da jemljete zdravilo MAVENCLAD.
Do not store the tablets in a different container. 
Tablet ne shranite v drug vsebnik.
MAVENCLAD is a medicine used to treat multiple sclerosis (MS) in adults. 
Zdravilo MAVENCLAD se uporablja za zdravljenje multiple skleroze (MS) pri odraslih.
Tell your doctor immediately if you have symptoms of shingles such as a 'band' of severe pain and blistering rash, typically on one side of the upper body or the face. 
Nemudoma povejte zdravniku, če imate simptome pasovca, kot na primer 'pas' hude bolečine in mehurjastega izpuščaja, običajno na eni strani zgornjega dela trupa ali obraza.
See also 'Other medicines and MAVENCLAD'. 
Glejte tudi 'Druga zdravila in zdravilo MAVENCLAD'.
Secondary progressive MS with relapses 
Sekundarna progresivna MS z recidivi
Histologically, testicular degeneration was only seen in one male monkey in a 1-year subcutaneous toxicity study. 
Histološko so testikularno degeneracijo opazili samo pri enem opičjem samcu v 1-letni študiji toksičnosti ob subkutani uporabi.
These included 
Vključevale so
As the tablets are uncoated, they must be swallowed immediately once removed from the blister and not be left exposed on surfaces or handled for any period of time greater than that required for dosing. 
Ker tablete niso obložene, jih je treba pogoltniti takoj, ko se odstranijo iz pretisnega omota, da ne ostanejo izpostavljene na površinah in da se z njimi ne rokuje dlje časa, kot je to potrebno za odmerjanje.
The patient's hands must be dry when handling the tablets and washed thoroughly afterwards. 
Bolnikove roke morajo biti suhe, ko rokuje s tabletami, nato pa jih mora temeljito oprati.
Example: If you forget to take the Day 3 dose and do not remember it until Day 4, take the Day 3 dose on Day 4, and extend the total number of days in the treatment week by 1 day. 
Primer: Če pozabite vzeti odmerek za 3. dan in se tega ne spomnite do 4. dne, boste odmerek za 3. dan vzeli 4. dan in skupno število dni v tednu zdravljenja podaljšali za en dan.
If this recovery takes more than 6 months, the patient should not receive MAVENCLAD anymore. 
Če je za izboljšanje potrebnih več kot 6 mesecev, bolnik ne sme več prejemati zdravila MAVENCLAD.
Do not take MAVENCLAD if you are pregnant or trying to become pregnant. 
Ne jemljite zdravila MAVENCLAD, če ste noseči ali želite zanositi.
Before you start a treatment course, your doctor will do a blood test to check that the levels of lymphocytes (a type of white blood cells) are in an acceptable range. 
Preden boste lahko začeli s ciklusom zdravljenja, bo zdravnik opravil krvne preiskave, da preveri, ali so ravni limfocitov (vrsta belih krvnih celic) v sprejemljivem razponu.
- if you have a weakened immune system due to medical conditions or because you are taking other medicines that weaken your immune system or reduce the production of blood cells in your bone marrow. 
- če imate oslabljen imunski sistem zaradi bolezni ali ker jemljete zdravila, ki slabijo vaš imunski sistem ali zmanjšajo proizvodnjo krvnih celic v vašem kostnem mozgu.
(2) Push in the hooks on the sides of the carton simultaneously with your index finger and thumb, and keep hooks pushed. 
(2) Zatiča ob straneh škatle s palcem in kazalcem istočasno pritisnite noter in ju držite pritisnjena.
Keep your tablets in the blister until your next dose. 
Tablete hranite v pretisnem omotu do naslednjega odmerka.
Active chronic infection (tuberculosis or hepatitis). 
Aktivna kronična okužba (tuberkuloza ali hepatitis).
Read the 'Step-by-Step Guide' at the end of this package leaflet on how to handle the childresistant package and how to take the tablets included in the pack. 
Preberite 'Navodilo po korakih' na koncu tega navodila o tem, kako ravnati z za otroke varno ovojnino in kako jemati tablete, ki so v pakiranju.
• patients with 1 relapse in the previous year and at least 1 T1 Gd+ lesion or 9 or more T2 lesions, 
• bolnike z 1 recidivom v preteklem letu in vsaj 1 lezijo T1 Gd+ ali z 9 ali več lezijami T2 med zdravljenjem z drugimi DMD,
Each treatment week consists of 4 or 5 days on which a patient receives 10 mg or 20 mg (one or two tablets) as a single daily dose, depending on body weight. 
Vsak teden zdravljenja je sestavljen iz 4 ali 5 dni, ko bolnik prejme 10 mg ali 20 mg (eno ali dve tableti) kot enkratni dnevni odmerek, odvisno od telesne mase.
Progressive multifocal leukoencephalopathy (PML) If you believe your MS is getting worse or if you notice any new symptoms, for example changes in mood or behaviour, memory lapses, speech and communication difficulties, talk to your doctor as soon as possible. 
Če imate občutek, da se vaša MS slabša ali opazite nove simptome, na primer spremembe v razpoloženju ali vedenju, izgubo spomina, težave z govorom in komuniciranjem, se čim prej pogovorite z zdravnikom.
The incidence of affected mouse foetuses in this study was in the same range of spontaneous incidence of amelia and phocomelia in this strain of mice. 
Pogostnost prizadetih mišjih zarodkov v tej študiji je bila v istem razponu kot spontana pogostnost amelije in fokomelije v tem rodu miši.
If your doctor believes that MAVENCLAD is essential for you, your doctor will advise you to stop breast-feeding. 
Če zdravnik meni, da je zdravilo MAVENCLAD za vas bistvenega pomena, vam bo svetoval, da nehate dojiti.
Do not use MAVENCLAD together with other medicines for MS unless specifically advised by your doctor. 
Ne uporabljajte zdravila MAVENCLAD skupaj z drugimi zdravili za MS, razen če vam tega ni posebej svetoval zdravnik.
Cladribine and/or its phosphorylated metabolites are substantially accumulated and retained in human lymphocytes. 
Kladribin in/ali njegovi fosforilirani presnovki se v veliki meri kopičijo in zadržujejo v človeških limfocitih.
Patients with current active malignancies must not receive Mavenclad treatment; 
se bolniki z obstoječimi aktivnimi malignostmi ne smejo zdraviti z zdravilom Mavenclad;
Treatment with MAVENCLAD should not be initiated within 4 to 6 weeks after vaccination with live or attenuated live vaccines because of a risk of active vaccine infection. 
Zdravljenja z zdravilom MAVENCLAD se ne sme uvesti v roku 4 do 6 tednov po cepljenju z živimi ali oslabljenimi živimi cepivi zaradi tveganja okužbe z aktivnim cepivom.
Tablets must be swallowed whole and not chewed or allowed to dissolve in your mouth. 
Tablete morate pogoltniti cele in jih ne smete žvečiti ali pustiti, da se razpustijo v ustih.
The Patient Guide should include an introduction to Mavenclad treatment, its side effects, potential risks and information on pregnancy prevention. 
Vodnik za bolnika naj vključuje uvod v zdravljenje z zdravilom Mavenclad, njegove neželene učinke, možna tveganja in informacije o preprečevanju nosečnosti.
The distribution of cladribine across biological membranes is facilitated by various transport proteins, including ENT1, CNT3 and BCRP. 
Porazdelitev kladribina preko bioloških membran olajšajo različne transportne beljakovine, vključno z ENT1, CNT3 in BCRP.
Only traces of other metabolites could be found in plasma and in urine. 
Druge presnovke je mogoče najti v plazmi in v urinu le v sledeh.
The remaining patients were pre-treated with either interferon beta-1a, interferon beta-1b, glatiramer acetate or natalizumab. 
Preostali bolniki so bili predhodno zdravljeni bodisi z interferonom beta-1a, interferonom beta-1b, glatiramer acetatom ali natalizumabom.
What MAVENCLAD is and what it is used for What you need to know before you take MAVENCLAD How to take MAVENCLAD Possible side effects 
Kaj je zdravilo MAVENCLAD in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo MAVENCLAD Kako jemati zdravilo MAVENCLAD Možni neželeni učinki
If you miss a dose and you remember on the same day you were supposed to take it 
Če izpustite odmerek in se tega spomnite še isti dan, ko bi ga morali vzeti
The volume of distribution is large, indicating extensive tissue distribution and intracellular uptake. 
Volumen porazdelitve je velik, kar kaže na ekstenzivno porazdelitev v tkivih in intracelularni privzem.
Over two thirds of the study patients were treatment-naive for MS disease-modifying drugs (DMDs). 
Več kot dve tretjini bolnikov, ki so bili vključeni v študijo se pred tem ni zdravilo z zdravili za MS, ki spreminjajo potek bolezni (disease-modifying drugs - DMD).
Symptoms of infections can include: fever, aching, painful muscles, headache, generally feeling unwell or loss of appetite. 
Simptomi okužbe lahko vključujejo: zvišano telesno temperaturo, bolečine, boleče mišice, glavobol, splošno slabo počutje ali izgubo apetita.
Following both oral and intravenous administration, the parent compound cladribine was the main component present in plasma and urine. 
Tako po peroralnem kot po intravenskem dajanju je bila izhodna spojina kladribina glavna sestavina, prisotna v plazmi in urinu.
For treatment decisions based on the patient's lymphocyte counts, see section 4.2 and subsection 'Infections' below. 
Za odločitve o zdravljenju na podlagi bolnikovega števila limfocitov glejte poglavje 4.2 in spodnje podpoglavje 'Okužbe'.
The European Medicines Agency has waived the obligation to submit the results of studies with MAVENCLAD in all subsets of the paediatric population in multiple sclerosis (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom MAVENCLAD za vse podskupine pediatrične populacije z multiplo sklerozo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Do not start MAVENCLAD together with medicines that weaken your immune system or reduce the production of blood cells by your bone marrow. 
Ne začnite jemati zdravila MAVENCLAD skupaj z zdravili, ki slabijo vaš imunski sistem ali zmanjšajo proizvodnjo krvnih celic v vašem kostnem mozgu.
Non-clinical safety pharmacological and toxicological assessment of cladribine in animal models relevant for the safety assessment of cladribine did not yield significant findings other than those predicted by the pharmacologic mechanism of cladribine. 
Predklinična farmakološka in toksikološka ocena varnosti kladribina na živalskih modelih, pomembna za oceno varnosti kladribina, ni pokazala pomembnih ugotovitev, razen tistih, ki so bile pričakovane zaradi farmakološkega mehanizma kladribina.
Prior to launch of Mavenclad (cladribine) in each Member State (MS) the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational materials (EM), including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority (NCA). 
Pred uvedbo zdravila Mavenclad (kladribin) se mora imetnik dovoljenja za promet v vsaki državi članici s pristojnim nacionalnim organom dogovoriti o vsebini in obliki izobraževalnega gradiva, vključno s komunikacijskimi mediji, načini razdeljevanja in drugimi vidiki programa.
You will be given MAVENCLAD as two treatment courses over 2 years. 
Zdravilo MAVENCLAD boste dobili v dveh ciklusih zdravljenja v obdobju 2 let.
The doctor will also do blood tests during and after treatment to check that you can continue to take MAVENCLAD, and that you are not developing any complications from the treatment. 
Zdravnik bo krvne preiskave opravil tudi med zdravljenjem in po njem, da preveri, ali lahko nadaljujete z jemanjem zdravila MAVENCLAD in da se pri vas niso pojavili kakršni koli zapleti zaradi zdravljenja.
Inhibition of these enzymes or genetic polymorphisms (e.g. CYP2D6, CYP2C9 or CYP2C19) are not expected to result in clinically significant effects on cladribine pharmacokinetics or exposure. 
Ne pričakuje se, da bi zaviranje teh encimov ali genetskih polimorfizmov (npr. CYP2D6, CYP2C9 ali CYP2C19) povzročilo klinično pomembne učinke na farmakokinetiko kladribina ali izpostavljenost kladribinu.
Table 3 shows how many tablets (1 or 2 tablets) you have to take on each day. 
Preglednica 3 prikazuje število tablet (1 ali 2 tableti), ki ju morate vzeti v določenem dnevu.
Very rare (<1/10,000) 
Zelo redki (< 1/10.000)
Following oral administration, cladribine is rapidly absorbed. 
Po peroralnem dajanju se kladribin hitro absorbira.
If you have been vaccinated within the last 4 to 6 weeks, MAVENCLAD therapy must be delayed. 
Če ste se v zadnjih 4 do 6 tednih cepili, je treba zdravljenje z zdravilom MAVENCLAD prestaviti.
Each tablet contains 64 mg sorbitol. 
Ena tableta vsebuje 64 mg sorbitola.
This is important because MAVENCLAD may seriously harm your baby. 
To je pomembno, ker zdravilo MAVENCLAD lahko resno škoduje vašemu otroku.
Subsequent phosphorylation of cladribine to its active triphosphate form, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), is particularly efficiently achieved in lymphocytes, due to their constitutively high deoxycytidine kinase (DCK) and relatively low 5'-nucleotidase (5'-NTase) levels. 
Naknadna fosforilacija kladribina v njegovo aktivno trifosfatno obliko 2-klorodeoksiadenozin trifosfat (Cd-ATP) je posebej učinkovito dosežena v limfocitih, zaradi njihovih osnovno visokih ravni deoksicitidin kinaze (dCK) in relativno nizkih ravni 5'-nukleotidaze (5'-NTaza).
Dose in mg (number of 10 mg tablets) per treatment week kg 
Odmerek v mg (število 10 mg tablet) na teden zdravljenja kg
- The other ingredients are hydroxypropylbetadex, sorbitol and magnesium stearate. 
- Druge sestavine so hidroksipropilbetadeks, sorbitol in magnezijev stearat.
Receive counselling before starting the treatment (consisting of two treatment courses administered at the beginning of two consecutive years) both in year 1 and year 2; 
prejmejo svetovanje pred začetkom zdravljenja (sestavljeno iz dveh ciklov zdravljenja, ko bolnik zdravilo prejema na začetku dveh zaporednih let) tako 1. leto kot 2. leto;
A missed dose must be taken as soon as remembered on the same day according to the treatment schedule. 
Izpuščeni odmerek je treba nadoknaditi takoj, ko se bolnik tega spomni, istega dne v skladu z režimom zdravljenja.
Caution: Do not remove the tray from the carton. 
Pozor: Nosilca ne odstranite iz škatle.
Based on pooled population pharmacokinetic data from various studies, the median values for elimination were 22.2 L/h for renal clearance and 23.4 L/h for non-renal clearance. 
Na podlagi populacijskih farmakokinetičnih podatkov, združenih iz različnih študij, je bila mediana vrednost za izločanje 22,2 l/h za ledvični očistek in 23,4 l/h za neledvični očistek.
It is not known whether cladribine is excreted in human milk. 
Ni znano, ali se kladribin izloča v materino mleko.
It is expected that most patients recover to either normal lymphocyte counts or grade 1 lymphopenia within 9 months. 
Pričakovati je, da v roku 9 mesecev večina bolnikov okreva bodisi na normalno število limfocitov ali na limfopenijo 1. stopnje.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Do not take MAVENCLAD and talk to your doctor or pharmacist if you are unsure if any of the above applies to you. 
Ne jemljite zdravila MAVENCLAD in se posvetujte z zdravnikom ali farmacevtom, če ste negotovi, ali kar koli od naštetega velja za vas.
Cladribine is a prodrug that has to be phosphorylated intracellularly to become biologically active. 
Kladribin je predzdravilo, ki se mora intracelularno fosforilirati, da postane biološko učinkovito.
Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4 (see section 5.1). 
Po zaključku 2 ciklusov zdravljenja nadaljnje zdravljenje s kladribinom v 3. in 4. letu ni potrebno (glejte poglavje 5.1).
In vivo clastogenicity in mice was detected at 10 mg/kg, which was the lowest dose tested. 
Klastogenost in vivo pri miših so zaznali pri 10 mg/kg, kar je bil najmanjši testirani odmerek.
Tell your doctor immediately if you get symptoms of shingles, a common complication of MAVENCLAD (see section 4), which may need specific treatment. 
Takoj povejte zdravniku, če imate simptome pasovcaa, pogostega zapleta pri zdravilu MAVENCLAD (glejte poglavje 4), za katerega bo morda potrebno posebno zdravljenje.
This is important because MAVENCLAD can seriously harm your baby. 
To je pomembno, ker lahko zdravilo MAVENCLAD resno škoduje vašemu otroku.
In hepatic in vitro systems, negligible metabolism of cladribine was observed (at least 90% was unchanged cladribine). 
V jetrnih sistemih in vitro so opazili zanemarljivo presnovo kladribina (vsaj 90 % je bilo nespremenjenega kladribina).
110 kg and above 
110 kg in več
- if you have active tuberculosis or liver inflammation (hepatitis). 
- če imate aktivno tuberkulozo ali vnetje jeter (hepatitis).
What MAVENCLAD is and what it is used for 
Kaj je zdravilo MAVENCLAD in za kaj ga uporabljamo
If the lymphocyte count is below 
Če je število limfocitov pod
Safety and efficacy of MAVENCLAD in combination with other disease-modifying treatments for MS have not been established. 
Varnost in učinkovitost zdravila MAVENCLAD v kombinaciji z drugimi oblikami zdravljenja, ki spreminjajo potek MS, nista bili dokazani.
• An introduction to Mavenclad, reminding the prescriber to consider the Patient Guide while discussing Mavenclad treatment with the patient, to support the early identification of sign and symptoms of adverse reactions and their timely treatment; 
• uvod v zdravljenje z zdravilom Mavenclad, ki zdravnika, ki bo zdravilo predpisoval, opozori, da naj med pogovorom z bolnikom glede uporabe zdravila Mavenclad upošteva vodnik za bolnika v podporo zgodnjega odkrivanja znakov in simptomov neželenih učinkov in njihovega pravočasnega zdravljenja;
The carcinogenic potential of cladribine was assessed in a long-term 22-month study with subcutaneous administration in mice and in a short-term 26-week study by oral route in transgenic mice. 
Kancerogeni potencial kladribina so ocenili v dolgoročni 22-mesečni študiji s subkutano uporabo pri miših in v kratkoročni 26-tedenski študiji s peroralno uporabo pri transgenih miših.
MAVENCLAD tablets are white, round, biconvex tablets engraved with 'C' on one side and '10' on the other side. 
Zdravilo MAVENCLAD so bele, okrogle, bikonveksne tablete z vtisnjeno oznako 'C' na eni strani in '10' na drugi.
• at least 800 cells/mm³ before initiating MAVENCLAD in year 2. 
• najmanj 800 celic/mm³ pred uvedbo zdravila MAVENCLAD v 2. letu.
Do not take MAVENCLAD: 
Ne jemljite zdravila MAVENCLAD:
MAVENCLAD is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features (see section 5.1). 
Zdravilo MAVENCLAD je indicirano za zdravljenje odraslih bolnikov z zelo aktivno recidivno multiplo sklerozo (MS), kot je opredeljena s kliničnimi ali slikovnimi značilnostmi (glejte poglavje 5.1).
Patients treated with MAVENCLAD should be advised to follow standard cancer screening guidelines. 
Bolnikom, ki prejemajo MAVENCLAD, je treba svetovati, da upoštevajo standardne smernice glede presejalnih pregledov za raka.
In a study of the intracellular pharmacokinetics of Cd-AMP and Cd-ATP in patients with chronic myelogenous leukaemia, the levels of Cd-ATP were approximately half of the Cd-AMP levels. 
V študiji intracelularne farmakokinetike Cd-AMP in Cd-ATP pri bolnikih s kronično mielogeno levkemijo so bile ravni Cd-ATP približno polovica ravni Cd-AMP.
Changing treatments 
Spreminjanje zdravljenja
Pharmacokinetic interactions 
Farmakokinetične interakcije